Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 Recruiting
24 enrolled
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/2 Recruiting
15 enrolled
DP-04
Recruiting
100 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2 Recruiting
25 enrolled
3D Printed Custom Applicators for HDR BT (DISCO)
Phase NA Recruiting
10 enrolled
iCaRe2
Recruiting
999,999 enrolled
Image-Guided Gynecologic Brachytherapy
Phase NA Recruiting
54 enrolled
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Phase 2 Recruiting
32 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
MIPEX
Phase NA Recruiting
64 enrolled
ASQ-GYO
Phase NA Recruiting
70 enrolled
DOVE
Phase 2 Recruiting
198 enrolled
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Phase NA Recruiting
192 enrolled
Reiki-Brachy
Phase 2 Recruiting
68 enrolled
NYSCF Scientific Discovery Biobank
Recruiting
10,000 enrolled
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Recruiting
6,000 enrolled
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Phase 2 Recruiting
40 enrolled
HPV-VIM
Phase 2 Recruiting
85 enrolled
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Phase 1 Recruiting
18 enrolled
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3 Recruiting
8,000 enrolled
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Phase 3 Recruiting
1,200 enrolled
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3 Recruiting
1,348 enrolled
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Recruiting
600 enrolled
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Phase 1 Recruiting
32 enrolled
RetroBT
Recruiting
300 enrolled